- Home
- NMCO vs FULC Comparison
NMCO vs FULC Comparison
Compare NMCO & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | FULC |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 468.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NMCO | FULC |
|---|---|---|
| Price | $10.39 | $9.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 207.6K | ★ 2.6M |
| Earning Date | 01-01-0001 | 02-24-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2752.05 |
| 52 Week Low | $8.52 | $2.32 |
| 52 Week High | $11.64 | $15.74 |
Technical Indicators
Market Signals| Indicator | NMCO | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 40.85 |
| Support Level | $10.17 | $11.71 |
| Resistance Level | $10.36 | $12.27 |
| Average True Range (ATR) | 0.10 | 0.71 |
| MACD | 0.02 | -0.34 |
| Stochastic Oscillator | 84.48 | 9.42 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.